North American indapamide market is estimated to grow significantly at a CAGR of around 0.3% during the forecast period. The market is mainly growing due to the rising prevalence of hypertension and CVD such as heart strokes, blood pressure, arrhythmias among others. According to the Heart & Stroke Foundation in Canada (2017), 1.6 million fatalities occur every year due to stroke and at least 1.3 million Canadians live with heart disease. Further, the population is also more inclined to the risk of heart strokes. According to WHO, the incidence and prevalence rate of heart attacks are the highest in North America, which is responsible for 700,000 fatalities each year. Moreover, the rate of adoption of advanced techniques is the highest in North America which in turn supports the growth of the market in North America.
To Request a Sample of our Report on North American Indapamide Market: https://www.omrglobal.com/request-sample/north-american-indapamide-market
The North American indapamide market is segmented on the basis of product and application. Based on product, the market is bifurcated into 1.25 mg and 2.5 mg. Among these, the market for 1.25 mg medicine held the significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.
(Get 15% Discount on Buying this Report)
A full Report of North American Indapamide Market is Available at: https://www.omrglobal.com/industry-reports/north-american-indapamide-market
North American Indapamide Market Segmentation
By Product
- 1.25 MG
- 2.5 MG
By Application
- High Blood Pressure
- Heart Failure
- Others
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
